GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Abeona Therapeutics Inc. (ABEO) [hlAlert]

Rating:
Buy ABEO
up 27.71 %

Abeona Therapeutics Inc. (ABEO) rated Buy with price target $6 by Maxim Group

Posted on: Wednesday,  Dec 16, 2015  8:25 AM ET by Maxim Group

Maxim Group rated Buy Abeona Therapeutics Inc. (NASDAQ: ABEO) on 12/16/2015, when the stock price was $3.68. Since
then, Abeona Therapeutics Inc. has gained 27.72% as of 12/16/2015's recent price of $4.70.
If you would have followed this Maxim Group's recommendation on ABEO, you would have gained 27.71% of your investment in 0 days.

Access Pharmaceuticals, Inc. (Access) is a biopharmaceutical company focused on developing products based upon its nanopolymer chemistry technologies and other drug delivery technologies. As of December 31, 2008, the Company has one approved product, one product at Phase III of clinical development, four products in Phase II of clinical development, and four products in pre-clinical development. On January 4, 2008, the Company acquired Somanta Pharmaceuticals, Inc. On February 25, 2009, Access acquired MacroChem Corporation.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/16/2015 8:25 AM Buy
None
3.68 6.00
as of 1/1/0001
1 Week   
1 Month   
3 Months   
1 YTD   

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy